(ELTX) Elicio Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US28657F1030
Stock: Cancer Vaccines, Peptide Therapy, KRAS Targeting, BRAF Targeting, TP53 Targeting
Total Rating 16
Risk 47
Buy Signal -0.64
| Risk 5d forecast | |
|---|---|
| Volatility | 109% |
| Relative Tail Risk | -23.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -19.59 |
| Character TTM | |
|---|---|
| Beta | 0.306 |
| Beta Downside | -0.228 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.81% |
| CAGR/Max DD | 0.09 |
Description: ELTX Elicio Therapeutics January 18, 2026
Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a Boston-based clinical-stage biotech focused on lymph-node-targeted amphiphile (AMP) peptide vaccines for cancer. Its lead candidate, ELI-002, is in a Phase II trial targeting seven KRAS driver mutations. Preclinical programs include ELI-007 for BRAF-mutant tumors and ELI-008 for TP53-mutant cancers.
As of the latest Q2 2024 filing, ELTX reported $48 million of cash and equivalents, providing roughly 10 months of runway at its current burn rate of $5 million per quarter. The cancer immunotherapy market is projected to exceed $200 billion by 2028, driven by increasing FDA support for personalized vaccines and a growing pipeline of combination-therapy trials. Elicio’s AMP platform differentiates itself by delivering antigens directly to lymph nodes, a mechanistic advantage that could improve response rates relative to conventional peptide vaccines.
For a deeper, data-driven assessment of ELTX’s valuation metrics, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -45.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.38 > 0.02 and ΔFCF/TA -38.02 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.38 > 3% & CFO -38.9m > Net Income -45.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (16.7m) vs 12m ago 22.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.50% > 50% (prev 0.0%; Δ 3.50% > 0%) |
| Interest Coverage Ratio: -43.52 > 6 (EBITDA TTM -43.7m / Interest Expense TTM 1.03m) |
Altman Z'' -15.00
| A: 0.53 (Total Current Assets 21.5m - Total Current Liabilities 6.51m) / Total Assets 28.3m |
| B: -7.99 (Retained Earnings -226.0m / Total Assets 28.3m) |
| C: -1.34 (EBIT TTM -44.8m / Avg Total Assets 33.3m) |
| D: -9.23 (Book Value of Equity -225.8m / Total Liabilities 24.5m) |
| Altman-Z'' Score: -41.30 = D |
What is the price of ELTX shares?
As of February 08, 2026, the stock is trading at USD 8.32 with a total of 115,820 shares traded.
Over the past week, the price has changed by +9.47%, over one month by +3.10%, over three months by -8.27% and over the past year by -11.49%.
Over the past week, the price has changed by +9.47%, over one month by +3.10%, over three months by -8.27% and over the past year by -11.49%.
Is ELTX a buy, sell or hold?
Elicio Therapeutics has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy ELTX.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.5 | 86.3% |
| Analysts Target Price | 15.5 | 86.3% |
| ValueRay Target Price | 7.9 | -4.7% |
ELTX Fundamental Data Overview February 04, 2026
P/B = 34.6213
Revenue TTM = 1.17m USD
EBIT TTM = -44.8m USD
EBITDA TTM = -43.7m USD
Long Term Debt = 9.72m USD (from longTermDebt, last quarter)
Short Term Debt = 981.0k USD (from shortTermDebt, last quarter)
Debt = 5.34m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -15.3m USD (from netDebt column, last quarter)
Enterprise Value = 124.5m USD (139.8m + Debt 5.34m - CCE 20.6m)
Interest Coverage Ratio = -43.52 (Ebit TTM -44.8m / Interest Expense TTM 1.03m)
EV/FCF = -3.20x (Enterprise Value 124.5m / FCF TTM -38.9m)
FCF Yield = -31.28% (FCF TTM -38.9m / Enterprise Value 124.5m)
FCF Margin = -3340 % (FCF TTM -38.9m / Revenue TTM 1.17m)
Net Margin = -3933 % (Net Income TTM -45.9m / Revenue TTM 1.17m)
Gross Margin = 1.63% ((Revenue TTM 1.17m - Cost of Revenue TTM 1.15m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.40 (Enterprise Value 124.5m / Total Assets 28.3m)
Interest Expense / Debt = 7.98% (Interest Expense 426.0k / Debt 5.34m)
Taxrate = 21.0% (US default 21%)
NOPAT = -35.4m (EBIT -44.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.29 (Total Current Assets 21.5m / Total Current Liabilities 6.51m)
Debt / Equity = 1.40 (Debt 5.34m / totalStockholderEquity, last quarter 3.82m)
Debt / EBITDA = 0.35 (negative EBITDA) (Net Debt -15.3m / EBITDA -43.7m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -15.3m / FCF TTM -38.9m)
Total Stockholder Equity = 810.5k (last 4 quarters mean from totalStockholderEquity)
RoA = -137.6% (out of range, set to none)
RoE = -5658 % (out of range, set to none) (Net Income TTM -45.9m / Total Stockholder Equity 810.5k)
RoCE = -425.7% (out of range, set to none) (EBIT -44.8m / Capital Employed (Equity 810.5k + L.T.Debt 9.72m))
RoIC = -334.6% (out of range, set to none) (NOPAT -35.4m / Invested Capital 10.6m)
WACC = 7.01% (E(139.8m)/V(145.1m) * Re(7.04%) + D(5.34m)/V(145.1m) * Rd(7.98%) * (1-Tc(0.21)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 31.84%
Fair Price DCF = unknown (Cash Flow -38.9m)
EPS Correlation: 92.50 | EPS CAGR: 154.5% | SUE: 0.19 | # QB: 0
Revenue Correlation: -45.62 | Revenue CAGR: -47.24% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.42 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.50 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+39.9% | Growth Revenue=+0.0%
Revenue TTM = 1.17m USD
EBIT TTM = -44.8m USD
EBITDA TTM = -43.7m USD
Long Term Debt = 9.72m USD (from longTermDebt, last quarter)
Short Term Debt = 981.0k USD (from shortTermDebt, last quarter)
Debt = 5.34m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -15.3m USD (from netDebt column, last quarter)
Enterprise Value = 124.5m USD (139.8m + Debt 5.34m - CCE 20.6m)
Interest Coverage Ratio = -43.52 (Ebit TTM -44.8m / Interest Expense TTM 1.03m)
EV/FCF = -3.20x (Enterprise Value 124.5m / FCF TTM -38.9m)
FCF Yield = -31.28% (FCF TTM -38.9m / Enterprise Value 124.5m)
FCF Margin = -3340 % (FCF TTM -38.9m / Revenue TTM 1.17m)
Net Margin = -3933 % (Net Income TTM -45.9m / Revenue TTM 1.17m)
Gross Margin = 1.63% ((Revenue TTM 1.17m - Cost of Revenue TTM 1.15m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.40 (Enterprise Value 124.5m / Total Assets 28.3m)
Interest Expense / Debt = 7.98% (Interest Expense 426.0k / Debt 5.34m)
Taxrate = 21.0% (US default 21%)
NOPAT = -35.4m (EBIT -44.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.29 (Total Current Assets 21.5m / Total Current Liabilities 6.51m)
Debt / Equity = 1.40 (Debt 5.34m / totalStockholderEquity, last quarter 3.82m)
Debt / EBITDA = 0.35 (negative EBITDA) (Net Debt -15.3m / EBITDA -43.7m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -15.3m / FCF TTM -38.9m)
Total Stockholder Equity = 810.5k (last 4 quarters mean from totalStockholderEquity)
RoA = -137.6% (out of range, set to none)
RoE = -5658 % (out of range, set to none) (Net Income TTM -45.9m / Total Stockholder Equity 810.5k)
RoCE = -425.7% (out of range, set to none) (EBIT -44.8m / Capital Employed (Equity 810.5k + L.T.Debt 9.72m))
RoIC = -334.6% (out of range, set to none) (NOPAT -35.4m / Invested Capital 10.6m)
WACC = 7.01% (E(139.8m)/V(145.1m) * Re(7.04%) + D(5.34m)/V(145.1m) * Rd(7.98%) * (1-Tc(0.21)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 31.84%
Fair Price DCF = unknown (Cash Flow -38.9m)
EPS Correlation: 92.50 | EPS CAGR: 154.5% | SUE: 0.19 | # QB: 0
Revenue Correlation: -45.62 | Revenue CAGR: -47.24% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.42 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.50 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+39.9% | Growth Revenue=+0.0%